A Focus on Skin Cancers

Wednesday, Sept. 6, 2023 | 1-5 P.M. EDT

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for skin cancers. Free for healthcare professionals, students, patients and patient advocates.

Register Now

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Program Organizers


Diwakar Davar, MD             UPMC Hillman Cancer Center


Siwen Hu-Lieskovan, MD, PhD University of Utah


Sapna Pradyuman Patel, MD The University of Texas MD Anderson Cancer Center

Program Agenda

1–1:05 p.m.



1:05–1:35 p.m.

  Moving Immunotherapy to an Earlier Line: Neoadjuvant vs Adjuvant Treatments, Stage II vs Stage III
Sapna Pradyuman Patel, MD – The University of Texas MD Anderson Cancer Center

1:352:05 p.m.


Front-line Therapy for Patients with Metastatic Melanoma
Evan J. Lipson, MD – Johns Hopkins University

2:052:35 p.m.


Treatment Beyond Progression: Second-line and Beyond
Jason J. Luke, MD, FACP – UPMC Hillman Cancer Center

2:35–3:05 p.m.


Non-melanoma Skin Cancer
Ann W. Silk, MD, MS – Dana-Farber Cancer Institute

3:05–3:20 p.m.



3:20–3:40 p.m.


Cancer Immunotherapy In Practice: irAEs and Management
Jordan McPherson, PharmD, MS, BCOP – Huntsman Cancer Institute

3:40–4 p.m.


Integrating Biomarkers in Clinical Practice: ctDNA and Beyond
Zeynep Eroglu, MD – Moffitt Cancer Center

4–5 p.m.   Faculty Case Study Panel

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.

  • Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and management.

  • Implement cancer immunotherapy for skin cancer into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful ABIM_Logo.jpgcompletion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.



Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.